Amneal Pharmaceuticals (AMRX) stock: analyst price target and their real reliability
Live quote · data updated Oct 14, 2026
Amneal Pharmaceuticals · Health Care · ref. ETF XLV · 50 calls · price $19.57
What the company does: Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products.
📈 Amneal Pharmaceuticals (AMRX) stock price
$19.57+101.3% over range
Oct 14, 25low $9.72 · high $20.5Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 4 analysts
📊 JPI status : Amneal Pharmaceuticals has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
🎯 AMRX price target & analyst consensus — price $19.57
The price target · all analysts combined (4 targets)
Highest target · 1 firm of 4$27+38.0%
Median target · of 4 targets$24+22.6%
Lowest target · 1 firm of 4$20+2.2%
Current price$19.57
Where these 4 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price
4100%
$20 ↔ $27
⭐ What the most reliable analysts say
· those who beat their sector, targets replayed on real prices
⭐ The most reliable of them, either direction: Leerink Partners — 64% of its targets hit on this sector (11 calls tested). It aims for $23 (+18 %), call made on September 10, 2026, maturing on September 10, 2027 (34 d ago).
The 2 reliable analysts
$24+23 %
The 2 other firms
$23.50+20 %
How to read it: the 2 reliable firms are not filtered by optimism — 2 aim above the price, 0 below, hence their $24 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 4 ratings (last 6 months)
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Go deeper on the analysts
🎯 AMRX price target all
All 50 calls, one by one, with our verdict on each firm.
→ See all 50 targets, analyst by analyst💡 The best analysts on AMRX most reliable
Their real reliability on AMRX, firm by firm: who was right, who was wrong.
→ See their reliability on AMRXAll analysts (the consensus) · vs · the best (those who've been right)
💬 A question about Amneal Pharmaceuticals? The JPI assistant answers using our backtest data.
🔎 Detailed analyses
✅ Historical analyst reliability on AMRX
Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.
| Firm ↕ | % right i ↕ | Gain vs sector i ↕ | Calls i ↕ |
|---|---|---|---|
| Truist Securities ↗ | 100% | +97.5% | 7 |
| Barclays ↗ | 100% | +84.9% | 5 |
| Piper Sandler ↗ | 83% | +62.2% | 6 |
| SunTrust Robinson Humphrey | 75% | +3.8% | 4 |
| JP Morgan ↗ | 67% | +36.1% | 3 |
| Raymond James ↗ | 67% | +6.1% | 3 |
| Goldman Sachs ↗ | 57% | +32.0% | 7 |
| Guggenheim ↗ | 0% | -7.6% | 2 |
| B. Riley Securities ↗ | 0% | -75.8% | 2 |
| Morgan Stanley ↗ | 0% | -83.2% | 2 |
📊 What $1,000 invested in Amneal Pharmaceuticals would be worth › open the full page
In short — $1,000 invested in Amneal Pharmaceuticals 10 years ago would be worth $1,135 today, i.e. +2%/yr on average. Best year: 2023 (+205%), worst: 2019 (-68%). Price performance, excluding dividends.
If I'd invested $1,000 in Amneal Pharmaceuticals
| Investment | Worth today | Gain |
|---|---|---|
| 1 years ago | $2,134 | +113% |
| 3 years ago | $8,387 | +739% |
| 5 years ago | $3,652 | +265% |
Return by year (Amneal Pharmaceuticals)
| Year | Return | $1,000 invested at year start |
|---|---|---|
| 2026 (YTD) | +32% | $1,318 (+32%) |
| 2025 | +62% | $2,134 (+113%) |
| 2024 | +29% | $2,750 (+175%) |
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.
📰 Recent news on Amneal Pharmaceuticals
Loading news…
📋 All analyst calls on AMRX
Filtered on — · ✕ show all
Oppenheimer ↗
Sep 23, 26
▲ Outperform · 🎯$27
Price at call : $19.33 — upside +40%
Today : $19.57 — upside +38%
🎯 on AMRX : no call matured yet · 📊 on Health : 47.4% · +5.9% (95 calls)
in progress (365j)
matures : Sep 23, 27
matures : Sep 23, 27
▲ Overweight · 🎯$20
Price at call : $18.28 — upside +9%
Today : $19.57 — upside +2%
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Sep 17, 27
matures : Sep 17, 27
Leerink Partners ↗
Sep 9, 26
▲ Outperform · 🎯$23
Price at call : $16.87 — upside +36%
Today : $19.57 — upside +18%
🎯 on AMRX : no call matured yet · 📊 on Health : 54.5% · +7.0% (11 calls)
in progress (365j)
matures : Sep 9, 27
matures : Sep 9, 27
▲ Buy · 🎯$25
Price at call : $18.48 — upside +35%
Today : $19.57 — upside +28%
🎯 on AMRX : no call matured yet · 📊 on Health : 48.7% · +2.2% (76 calls)
in progress (365j)
matures : Aug 3, 27
matures : Aug 3, 27
▲ Buy · 🎯$23
Price at call : $18.04 — upside +27%
Today : $19.57 — upside +18%
🎯 on AMRX : no call matured yet · 📊 on Health : 48.7% · +2.2% (76 calls)
in progress (365j)
matures : Jul 15, 27
matures : Jul 15, 27
▲ Overweight · 🎯$16
Price at call : $12.42 — upside +29%
Today : $19.57 — upside -18%
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : May 20, 27
matures : May 20, 27
▲ Buy · 🎯$19
Price at call : $13.91 — upside +37%
Today : $19.57 — upside -3%
🎯 on AMRX : no call matured yet · 📊 on Health : 48.7% · +2.2% (76 calls)
in progress (365j)
matures : Apr 17, 27
matures : Apr 17, 27
Truist Securities ↗
Mar 2, 26
▲ Buy · 🎯$17
Price at call : $13.77 — upside +23%
Today : $19.57 — upside -13%
🎯 on AMRX : 100% (7 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
in progress (365j)
matures : Mar 2, 27
matures : Mar 2, 27
See the other 42 calls, newest to oldest
▲ Overweight · 🎯$15
Price at call : $12.21 — upside +23%
Today : $19.57 — upside -23%
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Dec 9, 26
matures : Dec 9, 26
Piper Sandler ↗
Oct 31, 25
▲ Overweight · 🎯$13
Price at call : $11.19 — upside +16%
Today : $19.57 — upside -34%
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
in progress (365j)
matures : Oct 31, 26
matures : Oct 31, 26
▲ Overweight · 🎯$14
Price at call : $9.74 — upside +44%
Today : $19.57 — upside -28%
Expected +44% · Actual +86% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 67% (3 calls matureds) · 📊 on Health : 49% · +6.7% (149 calls)
+85.6%
stock +86% · XLV +23%
matured Sep 16, 26
▲ Overweight · 🎯$11
Price at call : $8.76 — upside +26%
Today : $19.57 — upside -44%
Expected +26% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
+51.9%
stock +52% · XLV +5%
matured Mar 3, 26
▲ Overweight · 🎯$12
Price at call : $8.3 — upside +45%
Today : $19.57 — upside -39%
Expected +45% · Actual +77% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 67% (3 calls matureds) · 📊 on Health : 49% · +6.7% (149 calls)
+76.6%
stock +77% · XLV +7%
matured Feb 24, 26
Piper Sandler ↗
Nov 11, 24
▲ Overweight · 🎯$11
Price at call : $9.2 — upside +20%
Today : $19.57 — upside -44%
Expected +20% · Actual +30% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+29.9%
stock +30% · XLV +1%
matured Nov 11, 25
Truist Securities ↗
Oct 2, 24
▲ Buy · 🎯$12
Price at call : $8.59 — upside +40%
Today : $19.57 — upside -39%
Expected +40% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (7 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
+21.1%
stock +21% · XLV -6%
matured Oct 2, 25
■ Neutral neutral · not a buy · 🎯$9
Price at call : $8.39 — gap to target +7%
Today : $19.57 — gap to target -54%
🎯 on AMRX : 67% (3 calls matureds) · 📊 on Health : 49% · +6.7% (149 calls)
in progress (365j)
matures : Sep 6, 25
matures : Sep 6, 25
▲ Overweight · 🎯$10
Price at call : $7.86 — upside +27%
Today : $19.57 — upside -49%
Expected +27% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
+19.6%
stock +20% · XLV -12%
matured Aug 13, 25
Truist Securities ↗
Aug 12, 24
▲ Buy · 🎯$10
Price at call : $7.54 — upside +33%
Today : $19.57 — upside -49%
Expected +33% · Actual +20% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (7 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
+19.6%
stock +20% · XLV -12%
matured Aug 12, 25
Goldman Sachs ↗
May 6, 24
▲ Buy · 🎯$8
Price at call : $6.51 — upside +23%
Today : $19.57 — upside -59%
Expected +23% · Actual +11% · Reason (≥ +15%) : ✗ No
🎯 on AMRX : 57% (7 calls matureds) · 📊 on Health : 51.9% · +5.8% (104 calls)
+10.9%
stock +11% · XLV -5%
matured May 6, 25
Truist Securities ↗
May 6, 24
▲ Buy · 🎯$9
Price at call : $6.65 — upside +35%
Today : $19.57 — upside -54%
Expected +35% · Actual +8% · Reason (≥ +15%) : ✗ No
🎯 on AMRX : 100% (7 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
+8.0%
stock +8% · XLV -5%
matured May 6, 25
Piper Sandler ↗
Mar 21, 24
▲ Overweight · 🎯$8
Price at call : $6.07 — upside +32%
Today : $19.57 — upside -59%
Expected +32% · Actual +46% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+46.5%
stock +46% · XLV +1%
matured Mar 21, 25
Goldman Sachs ↗
Mar 4, 24
▲ Buy · 🎯$6.25
Price at call : $5.4 — upside +16%
Today : $19.57 — upside -68%
Expected +16% · Actual +64% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 57% (7 calls matureds) · 📊 on Health : 51.9% · +5.8% (104 calls)
+63.7%
stock +64% · XLV +1%
matured Mar 4, 25
▲ Overweight · 🎯$8
Price at call : $5.76 — upside +39%
Today : $19.57 — upside -59%
Expected +39% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
+51.6%
stock +52% · XLV +4%
matured Jan 28, 25
Truist Securities ↗
Nov 8, 23
▲ Buy · 🎯$7
Price at call : $4.15 — upside +69%
Today : $19.57 — upside -64%
Expected +69% · Actual +110% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (7 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
+110.4%
stock +110% · XLV +20%
matured Nov 7, 24
Truist Securities ↗
Sep 6, 23
▲ Buy · 🎯$6
Price at call : $3.7 — upside +62%
Today : $19.57 — upside -69%
Expected +62% · Actual +127% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (7 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
+126.8%
stock +127% · XLV +17%
matured Sep 5, 24
Piper Sandler ↗
Aug 7, 23
▲ Overweight · 🎯$5
Price at call : $4.48 — upside +12%
Today : $19.57 — upside -74%
Expected +12% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+52.0%
stock +52% · XLV +8%
matured Aug 6, 24
Truist Securities ↗
Aug 7, 23
▲ Buy · 🎯$6
Price at call : $4.48 — upside +34%
Today : $19.57 — upside -69%
Expected +34% · Actual +52% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (7 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
+52.0%
stock +52% · XLV +8%
matured Aug 6, 24
▲ Overweight · 🎯$5
Price at call : $4.59 — upside +9%
Today : $19.57 — upside -74%
Expected +9% · Actual +50% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
+49.9%
stock +50% · XLV +10%
matured Aug 6, 24
Piper Sandler ↗
May 8, 23
▲ Overweight · 🎯$3
Price at call : $1.86 — upside +61%
Today : $19.57 — upside -85%
Expected +61% · Actual +254% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+254.3%
stock +254% · XLV +7%
matured May 7, 24
Truist Securities ↗
Mar 29, 23
▲ Buy · 🎯$4
Price at call : $1.36 — upside +194%
Today : $19.57 — upside -80%
Expected +194% · Actual +345% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (7 calls matureds) · 📊 on Health : 38.1% · -0.3% (168 calls)
+344.9%
stock +345% · XLV +14%
matured Mar 28, 24
▲ Overweight · 🎯$4
Price at call : $1.53 — upside +161%
Today : $19.57 — upside -80%
Expected +161% · Actual +252% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
+251.6%
stock +252% · XLV +18%
matured Mar 9, 24
Goldman Sachs ↗
Mar 3, 23
▲ Buy · 🎯$3
Price at call : $1.82 — upside +65%
Today : $19.57 — upside -85%
Expected +65% · Actual +197% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 57% (7 calls matureds) · 📊 on Health : 51.9% · +5.8% (104 calls)
+196.7%
stock +197% · XLV +13%
matured Mar 2, 24
BMO Capital ↗
Mar 3, 23
■ Market Perform neutral · not a buy · 🎯$4
Price at call : $1.92 — gap to target +108%
Today : $19.57 — gap to target -80%
🎯 on AMRX : no call matured yet · 📊 on Health : 43.3% · -2.2% (67 calls)
in progress (365j)
matures : Mar 2, 24
matures : Mar 2, 24
Goldman Sachs ↗
Aug 8, 22
▲ Buy · 🎯$4
Price at call : $3.13 — upside +28%
Today : $19.57 — upside -80%
Expected +28% · Actual +43% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 57% (7 calls matureds) · 📊 on Health : 51.9% · +5.8% (104 calls)
+43.1%
stock +43% · XLV +2%
matured Aug 8, 23
Goldman Sachs ↗
May 12, 22
▲ Buy · 🎯$4.5
Price at call : $3.4 — upside +32%
Today : $19.57 — upside -77%
Expected +32% · Actual -44% · Reason (≥ +15%) : ✗ No
🎯 on AMRX : 57% (7 calls matureds) · 📊 on Health : 51.9% · +5.8% (104 calls)
-43.5%
stock -44% · XLV +4%
matured May 12, 23
Goldman Sachs ↗
Mar 8, 21
▲ Buy · 🎯$6.5
Price at call : $5.6 — upside +16%
Today : $19.57 — upside -67%
Expected +16% · Actual -29% · Reason (≥ +15%) : ✗ No
🎯 on AMRX : 57% (7 calls matureds) · 📊 on Health : 51.9% · +5.8% (104 calls)
-28.7%
stock -29% · XLV +13%
matured Mar 8, 22
Guggenheim ↗
Dec 14, 20
▲ Buy
Actual -10% · Reason (≥ +15%) : ✗ No
🎯 on AMRX : 0% (1 call matured) · 📊 on Health : 64.7% · +17.5% (51 calls)
-10.0%
stock -10% · XLV +22%
matured Dec 14, 21
SVB Leerink
Nov 9, 20
■ Market Perform neutral · not a buy · 🎯$5.5
Price at call : $4.19 — gap to target +31%
Today : $19.57 — gap to target -72%
🎯 on AMRX : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Nov 9, 21
matures : Nov 9, 21
Piper Sandler ↗
Oct 9, 20
▲ Overweight · 🎯$6
Price at call : $4.75 — upside +26%
Today : $19.57 — upside -69%
Expected +26% · Actual +23% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+22.9%
stock +23% · XLV +16%
matured Oct 9, 21
Goldman Sachs ↗
Jul 27, 20
▼ Sell · 🎯$4
Price at call : $4.19 — upside -5%
Today : $19.57 — upside -80%
Expected -5% · Actual +18% · Reason (≤ −15%) : ✗ No
🎯 on AMRX : 57% (7 calls matureds) · 📊 on Health : 51.9% · +5.8% (104 calls)
-18.1%
stock +18% · XLV +25%
matured Jul 27, 21
SunTrust Robinson Humphrey
May 13, 20
▲ Buy · 🎯$5
Price at call : $4.36 — upside +15%
Today : $19.57 — upside -74%
Expected +15% · Actual +26% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (2 calls matureds) · 📊 unranked overall
+25.7%
stock +26% · XLV +25%
matured May 13, 21
Guggenheim ↗
May 12, 20
■ Neutral neutral · not a buy
🎯 on AMRX : 0% (1 call matured) · 📊 on Health : 64.7% · +17.5% (51 calls)
in progress (365j)
matures : May 12, 21
matures : May 12, 21
SVB Leerink
May 12, 20
■ Market Perform neutral · not a buy · 🎯$4
Price at call : $4.27 — gap to target -6%
Today : $19.57 — gap to target -80%
🎯 on AMRX : no call matured yet · 📊 unranked overall
in progress (365j)
matures : May 12, 21
matures : May 12, 21
Morgan Stanley ↗
Apr 2, 20
■ Equal-Weight neutral · not a buy · 🎯$3
Price at call : $3.05 — gap to target -2%
Today : $19.57 — gap to target -85%
🎯 on AMRX : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Apr 2, 21
matures : Apr 2, 21
SunTrust Robinson Humphrey
Feb 27, 20
▲ Buy · 🎯$5
Price at call : $3.85 — upside +30%
Today : $19.57 — upside -74%
Expected +30% · Actual +35% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (2 calls matureds) · 📊 unranked overall
+34.5%
stock +35% · XLV +23%
matured Feb 26, 21
RBC Capital ↗
Jan 2, 20
■ Sector Perform neutral · not a buy · 🎯$4
Price at call : $4.72 — gap to target -15%
Today : $19.57 — gap to target -80%
🎯 on AMRX : no call matured yet · 📊 on Health : 31.1% · -10.5% (167 calls)
in progress (365j)
matures : Jan 1, 21
matures : Jan 1, 21
Raymond James ↗
Dec 12, 19
■ Market Perform neutral · not a buy
🎯 on AMRX : 100% (1 call matured) · 📊 on Health : 39.7% · -2.1% (219 calls)
in progress (365j)
matures : Dec 11, 20
matures : Dec 11, 20
▼ Underweight
Actual +54% · Reason (≤ −15%) : ✗ No
🎯 on AMRX : 67% (3 calls matureds) · 📊 on Health : 49% · +6.7% (149 calls)
-54.1%
stock +54% · XLV +17%
matured Nov 11, 20
BMO Capital ↗
Nov 11, 19
■ Market Perform neutral · not a buy · 🎯$4
Price at call : $2.65 — gap to target +51%
Today : $19.57 — gap to target -80%
🎯 on AMRX : no call matured yet · 📊 on Health : 43.3% · -2.2% (67 calls)
in progress (365j)
matures : Nov 10, 20
matures : Nov 10, 20
Raymond James ↗
Nov 7, 19
▲ Outperform · 🎯$4
Price at call : $2.73 — upside +47%
Today : $19.57 — upside -80%
Expected +47% · Actual +53% · Reason (≥ +15%) : ✓ Yes
🎯 on AMRX : 100% (1 call matured) · 📊 on Health : 39.7% · -2.1% (219 calls)
+53.5%
stock +53% · XLV +17%
matured Nov 6, 20
Frequently asked questions
Should I buy Amneal Pharmaceuticals stock?
This isn't buy advice. For Amneal Pharmaceuticals, the analyst consensus is "Buy", with an average price target of $24.00 (+23% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (7 calls tracked on Amneal Pharmaceuticals). We show the numbers — you decide.
Is it too late to buy Amneal Pharmaceuticals? How high can it go?
The most bullish analyst target on Amneal Pharmaceuticals is $27.00 (+38% above today's price); the average is $24.00. That's the upside they see. Check how reliable those analysts have actually been on Amneal Pharmaceuticals on our site before trusting it.
Is Amneal Pharmaceuticals still a good buy?
The most useful "opinion" isn't an opinion — it's a track record: 10 analysts have a real record on Amneal Pharmaceuticals, the best hitting 100% over 7 calls. Current consensus: "Buy". Make your call on data, not noise.
What has Amneal Pharmaceuticals's past performance been?
Historical returns and a "how much if I had invested" calculator: AMRX performance & returns.
BIIB 
VRTX 
REGN 
UNH 
EW 
SRPT 
VEEV 
BSX